References
- Tummidi S, Kothari K, Rojekar A, et al. Multiple tuberous and tendinous xanthomas diagnosed on fine-needle aspiration cytology-report of a rare case. Diagn Cytopathol. 2019;47(9):939–942. doi:10.1002/dc.24219
- Zak A, Zeman M, Slaby A, et al. Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158(2):181–188. doi:10.5507/bp.2014.016
- Aljenedil S, Ruel I, Watters K, et al. Severe xanthomatosis in heterozygous familial hypercholesterolemia. J Clin Lipidol. 2018;12(4):872–877. doi:10.1016/j.jacl.2018.03.087
- Ribeiro RM, Vasconcelos SC, Lima P, et al. Pathophysiology and treatment of lipid abnormalities in cerebrotendinous xanthomatosis: an integrative review. Brain Sci. 2023;13(7):979. doi:10.3390/brainsci13070979
- Sato A, Tsukiyama T, Komeno M, et al. Generation of a familial hypercholesterolemia model in non-human primate. Sci Rep. 2023;13(1):15649. doi:10.1038/s41598-023-42763-1
- Harada-Shiba M, Arai H, Ishigaki Y, et al; Yokote K and Working Group by Japan Atherosclerosis Society for Making Guidance of Familial H. Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017. J Atheroscler Thromb. 2018;25(8):751–770. doi:10.5551/jat.CR003
- Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Familial hypercholesterolemia. Nat Rev Dis Primers. 2017;3(1):17093. doi:10.1038/nrdp.2017.93
- Dung PTV, Son TT, Thuy TTH, et al. Surgical treatment of multiple large tuberous xanthomas in familial hypercholesterolemia: a case report. Int J Surg Case Rep. 2021;89:106596. doi:10.1016/j.ijscr.2021.106596
- Zha S, Yu X, Wang X, et al. Topical simvastatin improves lesions of diffuse normolipemic plane xanthoma by inhibiting foam cell pyroptosis. Front Immunol. 2022;13:865704. doi:10.3389/fimmu.2022.865704
- Thadchanamoorthy V, Dayasiri K, Majitha SI, et al. Homozygous autosomal recessive hypercholesterolaemia in a South Asian child presenting with multiple cutaneous xanthomata. Ann Clin Biochem. 2021;58(2):153–156. doi:10.1177/0004563220961755
- Arca M, Celant S, Olimpieri PP, et al. Real-world effectiveness of PCSK9 inhibitors in reducing LDL-C in patients with familial hypercholesterolemia in Italy: a retrospective cohort study based on the AIFA Monitoring Registries. J Am Heart Assoc. 2023;12(21):e026550. doi:10.1161/JAHA.122.026550
- Raal F, Durst R, Bi R, et al. Efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia: results from the ORION-5 randomized clinical trial. Circulation. 2024;149(5):354–362. doi:10.1161/CIRCULATIONAHA.122.063460
- Nohara A, Tada H, Ogura M, et al. Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb. 2021;28(7):665–678. doi:10.5551/jat.RV17050